Sintesis Senyawa Kompleks Cu(II)-Hidrazon Berbasis Benzohidrazida dan Benzaldehida/Salisilaldehida sebagai Agen Kemoterapi

Alam, Yusuf Syahril (2022) Sintesis Senyawa Kompleks Cu(II)-Hidrazon Berbasis Benzohidrazida dan Benzaldehida/Salisilaldehida sebagai Agen Kemoterapi. Masters thesis, Institut Teknologi Sepuluh Nopember.

[thumbnail of 6004211014-Master_Thesis.pdf] Text
6004211014-Master_Thesis.pdf - Accepted Version
Restricted to Repository staff only until 1 July 2025.

Download (9MB) | Request a copy

Abstract

Kanker merupakan problematika global yang mengalami peningkatan prevalensi dan kematian setiap tahunnya. Saat ini, pengobatan kanker terkendala resistansi obat dan penggunaan logam berbasis platinum yang berdampak buruk bagi sistem dan organ tubuh. Pemanfaatan senyawa kompleks tembaga dapat menjadi solusi alternatif agen kemoterapi. Tembaga termasuk mikronutrien deret transisi yang sangat penting bagi tubuh dan berperan sentral dalam defisiensi angiogenesis. Di sisi lain, penentuan karakter ligan berpengaruh besar dalam bioaktivitas, khususnya antikanker. Pada penelitian ini telah berhasil disintesis senyawa kompleks Cu(II)-hidrazon dengan warna orange (2ASR) dan coklat (2BSR). Ligan hidrazon diperoleh dari hasil reaksi benzohidrazida dengan benzaldehid (1A) /salisilaldehid (1B). Analisis FTIR menunjukkan adanya ikatan logam dan ligan berupa Cu–N dan Cu–O pada bilangan gelombang 445-470 cm-1 dan 553-588 cm-1. Padatan kompleks menyerap sinar UV-Vis pada panjang gelombang 354 nm dan 394 nm. Fragmentasi spektroskopi massa menunjukkan perbandingan mol logam dan ligan sebesar 1:1. Hasil ini didukung data TGA dimana senyawa kompleks (2ASR) dan (2BSR) memiliki rumus molekul masing�masing [Cu(1A)(Cl (H2O)] dan [Cu(1B)Cl].H2O. Interpretasi powder XRD menunjukkan bahwa senyawa kompleks berbentuk polikristalin dan memiliki kemiripan dengan material standar. Uji antikanker dilakukan dengan metode PrestoBlue (PB) pada objek sel kanker serviks “HeLa”. Senyawa kompleks 2BSR mampu menghambat kanker paling optimum dengan IC50 sebesar 0,54 μg/mL.
=======================================================================================================================================
Cancer is a global problem with the prevalence and mortality increased every year. Currently, cancer treatment is limited by drug resistance and the use of platinum metal that negative impact on organs and body systems. The use of copper complexes could be an alternative solution of chemotherapy drugs. Copper is a transitional series micronutrient that is very important for the body and plays a central role in angiogenesis defects. On the other hand, the determination of the properties of the ligands has a big influence on the biological activity, especially anticancer. In this research, Cu(II)-hydrazone complexes was successfully synthesized with orange (2ASR) and brown (2BSR). The hydrazone ligand was obtained from the reaction of benzohydrazide with benzaldehyde (1A) / salicylaldehyde (1B). FTIR analysis revealed the presence of metal-ligand bonds in the form of Cu-N and Cu-O at wavenumbers 445-470 cm-1 and 553-588 cm-1. Complexes absorbs UV-Vis light at wavelengths of 354 nm and 394 nm Fragmentation mass spectra showed a 1:1 molar ratio of metal to ligand. These results were supported by TGA data, where the (2ASR) and (2BSR) complexes have the formulas [Cu(1A)(Cl)(H2O)] and [Cu(1B)Cl].H2O, respectively. Powder XRD interpretation shows that complexes was polycrystalline, with similarity to the reference material. Cervical cancer cell "HeLa" cancer cell test using PrestoBlue (PB) method. The 2BSR complexes optimally inhibits cancer with an IC50 of 0.54 μg/mL.

Item Type: Thesis (Masters)
Uncontrolled Keywords: Kanker; Kompleks tembaga; Hidrazon; Benzohidrazida; PrestoBlue Cancer; Copper complexes; Hydrazone; Benzohydrazide; PrestoBlue
Subjects: Q Science > QD Chemistry > QD251.2 Chemistry, Organic. Biochemistry
Q Science > QD Chemistry > QD471 Chemical compounds - Structure and formulas
Q Science > QD Chemistry > QD481 Chemical structure.
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Natural Science > Chemistry > 47101-(S2) Master Thesis
Depositing User: Yusuf Syahril Alam
Date Deposited: 17 Feb 2023 11:59
Last Modified: 17 Feb 2023 11:59
URI: http://repository.its.ac.id/id/eprint/97537

Actions (login required)

View Item View Item